A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.

Stein SchalkwijkRob Ter HeineAngela C ColbersAlwin D R HuitemaPaolo DentiKelly E DooleyEdmund CapparelliBrookie M BestTim R CresseyRick GreupinkFrans G M RusselMark MirochnickDavid M Burger

Published in: Clinical pharmacokinetics (2019)

It was predicted that reduced-dose efavirenz provides adequate exposure during pregnancy. These findings warrant prospective confirmation.

Keyphrases

pregnant women
hiv infected
antiretroviral therapy
hiv infected patients